SS-31 (Elamipretide)
Mechanism of Action and Research Overview
SS-31, also referred to in the literature as elamipretide, is a synthetic mitochondria-targeting tetrapeptide investigated as a research compound. Classified strictly as a Research Use Only (RUO) material, it is studied for its reported localization to the inner mitochondrial membrane and its interaction with cardiolipin. The published literature spans ophthalmologic, cardiac, and metabolic disease models.
Mechanism of Action
The mechanism most frequently described in published research centers on SS-31’s affinity for cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane. Cardiolipin is structurally important for the organization of the electron transport chain and for cristae architecture. Research describes SS-31 associating with cardiolipin and, in preclinical models, being studied for its reported effect on stabilizing this interaction and reducing cardiolipin-associated oxidative damage doi:10.3892/ijmm.2024.5436.
A second mechanistic theme in the literature concerns reactive oxygen species (ROS). Review work on age-related ocular models groups SS-31 among candidates studied for cytoprotective mechanisms, in the context of mitochondrial dysfunction and ROS accumulation associated with retinal pigment epithelium senescence PMID: 34572131. In these models, the compound is examined as a mitochondria-targeted antioxidant rather than a general free-radical scavenger, with targeting attributed to its physicochemical properties and membrane localization.
More recent preclinical research has examined SS-31 in relation to ferroptosis, an iron-dependent form of regulated cell death. In a diabetic cardiomyopathy model, researchers investigated SS-31 in connection with mitochondrial glutathione peroxidase 4 (mitoGPX4) activity and mitochondria-dependent ferroptosis, characterizing the compound as a mitochondria-targeting antioxidant under study for its reported effect on cardiolipin oxidative damage and ferroptosis-associated markers doi:10.3892/ijmm.2024.5436. These descriptions are mechanistic observations drawn from in vitro and in vivo model systems and do not constitute clinical conclusions.
Research Overview
Published findings on SS-31 come from several model systems. A 2021 review in Cells discussing therapeutic candidates for age-related macular degeneration (AMD) identifies SS-31/elamipretide among the compounds examined for cytoprotective mechanisms relevant to retinal aging, mitochondrial dysfunction, and ROS accumulation in retinal pigment epithelium PMID: 34572131. The review situates the compound within a broader list of investigational candidates rather than reporting it as an established intervention.
A 2024 study in the International Journal of Molecular Medicine investigated SS-31 in a diabetic cardiomyopathy (DCM) model. The work used H9C2 cardiac cells exposed to high-glucose conditions in vitro and a diabetic mouse model in vivo, examining changes in serum lactate dehydrogenase and creatine kinase isoenzymes, fractional shortening, and ejection fraction as measured endpoints. The reported focus was the relationship between SS-31, mitoGPX4 activation, and the alleviation of mitochondria-dependent ferroptosis doi:10.3892/ijmm.2024.5436.
Across both publications, the compound is consistently described in terms of mitochondrial targeting, cardiolipin interaction, and oxidative-stress-associated pathways. The body of literature remains preclinical, and the cited authors frame SS-31 as a research candidate whose mechanisms continue to be characterized in model systems.
Compound Characteristics
SS-31 is a water-soluble synthetic tetrapeptide belonging to the Szeto-Schiller (SS) peptide family. Its sequence incorporates alternating aromatic and basic residues, a structural feature associated in the literature with its reported ability to concentrate at the inner mitochondrial membrane independent of membrane potential. This membrane-targeting behavior is the property most often cited to distinguish it from non-targeted antioxidant compounds.
As a small peptide, SS-31 is handled in research settings according to standard peptide considerations, including storage as a lyophilized powder and reconstitution for laboratory use. Peptides of this class are generally characterized by sensitivity to temperature, repeated freeze-thaw cycles, and prolonged solution storage. Its cationic, amphipathic character is the basis for the cardiolipin affinity described in mechanistic studies.
Related Compounds
Several research compounds are studied alongside or in comparison with SS-31 based on overlapping mitochondrial or antioxidant research themes.
- MitoQ A mitochondria-targeted antioxidant constructed by conjugating a ubiquinone moiety to a lipophilic triphenylphosphonium cation. Studied in models of mitochondrial oxidative stress; represents an alternative chemical strategy for mitochondrial targeting compared with the peptide-based SS-31.
- SkQ1 Plastoquinonyl-decyl-triphenylphosphonium. A cation-targeted compound investigated in preclinical antioxidant and ocular research models, frequently grouped with mitochondria-directed agents.
- Szeto-Schiller peptides Structurally related tetrapeptides within the same family studied for inner-mitochondrial-membrane localization and cardiolipin interaction, providing comparative context for SS-31’s reported structure-activity relationships.
Listed for research comparison only. Inclusion reflects shared mechanistic study themes in the literature, not equivalence of properties.
Research Availability
SS-31 is offered as a Research Use Only material intended for in vitro and preclinical laboratory investigation by qualified researchers and institutions. Sourcing considerations for research use typically include certificate-of-analysis documentation, purity verification by HPLC and mass spectrometry, and appropriate handling and storage information. Material supplied for research is not intended for diagnostic, therapeutic, or human or veterinary use.